Loading…
Genomics company providing advanced tumor and immune profiling tests to guide cancer treatment and monitor recurrence.
Genomics company providing advanced tumor and immune profiling tests to guide cancer treatment and monitor recurrence.
Has long been paid mainly by drug developers for sequencing and tumour analysis in their trials, with a large share from one customer, Moderna. The NeXT Personal blood test, which looks for traces of cancer left after treatment, is the growth bet; its sales to clinicians depend on payers agreeing to cover it.
Moat: narrow (IP / patents, data). Proprietary highly-sensitive minimal-residual-disease test differentiates from broader liquid-biopsy competitors.
Headquarters: Fremont, California · Founded: 2011 · Employees: 260
Size Personalis (PSNL) is a United States Health Care company (Medical/Nursing Services) with a market value of $1.71B, the 1895th largest of 3,117 United States companies the cockpit tracks. Shares closed at $15.79 on 6 Nov 2026.
Performance Over six months the shares gained 164.1%, against +22.8% for the median peer and -1.1% for the United States market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue fell 13.3% over the last twelve months (peer median +5.9%); the operating margin is -164.1% (peer median 3.2%).
Valuation It trades at 22.1× enterprise value to sales against a peer median of 2.2× (most expensive of 21).
Capital Return on invested capital runs 165.9 points below its cost of capital (16.6% WACC).
Short interest Short interest is 6.3% of the free float (15 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $69.7M | $69.6M | $84.6M | $73.5M | $65.0M |
| Revenue growth | — | -18% | +15% | +13% | — |
| Gross profit | $8.84M | $15.8M | $26.8M | $18.2M | $13.3M |
| EBITDA | -$105M | -$78.0M | -$57.3M | -$85.0M | -$103M |
| Net income | -$107M | -$81.3M | -$81.3M | -$108M | -$113M |
| Free cash flow | -$101M | -$79.5M | -$46.8M | -$67.2M | -$120M |
| Capital expenditure | $8.68M | $4.50M | $1.60M | $10.9M | $49.9M |
| Total debt | $38.0M | $40.8M | $44.4M | $49.0M | $49.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Personalis PSNL | $1.71B | +164% | -13% | -164% | 22.1× | n/a |
| Guardant Health GH | $20.2B | +58% | +43% | -40% | 17.7× | n/a |
| Natera NTRA | $44.8B | +60% | +38% | -11% | 16.2× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PSNL | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.7% | +8.0% | 4th lowest of 21 |
| 6-month return | +164.1% | +22.8% | highest of 21 |
| Distance from 52-week high | -16.4% | -16.0% | 11th highest of 21 |
| Revenue growth (TTM) | -13.3% | +5.9% | lowest of 21 |
| Operating margin | -164.1% | 3.2% | lowest of 21 |
| EV / Sales | 22.1× | 2.2× | most expensive of 21 |
| ROIC minus cost of capital | -165.9 pp | -4.1 pp | lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Personalis PSNL | United States | $1.71B | +164% | -13% | -164% | 22.1× | n/a | n/a |
| Azenta AZTA | United States | $1.72B | +104% | +1% | -3% | 2.4× | 56.0% | +8.9% |
| Dr. Agarwal's Health Care AGARWALEYE.NS | India | $1.74B | +15% | +22% | 15% | 7.4× | 41.9% | +26.9% |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.63B | -47% | +8% | 3% | 0.7× | 15.0% | -5.1% |
| Ambea AMBEA.ST | Sweden | $1.63B | +30% | +13% | 8% | 1.7× | 1.7% | +7.7% |
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.60B | +22% | +24% | 32% | 16.8× | 39.3% | +16.7% |
| Teladoc Health TDOC | United States | $1.60B | +21% | -2% | -5% | 0.7× | -5.2% | +18.3% |
| Sonida Senior Living SNDA | United States | $1.58B | -14% | +49% | -11% | 5.9× | n/a | n/a |
| GeneDx WGS | United States | $1.86B | +53% | +25% | -12% | 4.2× | n/a | n/a |
| agilon health AGL | United States | $1.90B | +109% | 0% | -4% | 0.3× | n/a | n/a |
| Emeis EMEIS.PA | France | $1.94B | -30% | +4% | 3% | 1.6× | 21.3% | +8.5% |
| Dian Diagnostics 300244.SZ | China | $1.97B | +11% | -5% | 9% | 1.5× | 2.4% | -1.1% |
| U.S. Physical Therapy USPH | United States | $1.48B | +68% | +11% | 10% | 2.7× | 19.9% | +13.0% |
| Guangzhou Kingmed Diagnostics 603882.SS | China | $1.99B | +5% | -3% | 7% | 2.0× | 6.7% | -6.1% |
| Clariane CLARI.PA | France | $1.40B | -20% | +1% | 6% | 1.6× | 6.7% | +6.5% |
| H.U.Group 4544.T | Japan | $1.35B | +24% | +1% | 2% | 0.9× | 10.1% | +2.1% |
| NeoGenomics NEO | United States | $2.18B | +88% | +11% | -6% | 3.2× | n/a | n/a |
| Diagnostyka DIA.WA | Poland | $1.29B | -5% | +19% | 15% | 2.4× | 6.9% | +18.9% |
| OPKO Health OPK | United States | $1.29B | +52% | -11% | -29% | 2.4× | n/a | n/a |
| Lumexa Imaging LMRI | United States | $1.29B | +29% | +8% | 3% | 2.1× | n/a | n/a |
| AddLife ALIF-B.ST | Sweden | $2.29B | +25% | +2% | 8% | 2.5× | 21.6% | +14.6% |